| 摘要 |
The present invention relates to modified IgG molecules with an Fc domain or a fragment thereof derived from IgG2, IgG3 or IgG4, and having specific combinations of altered and wild-type amino acid residues, in particular Lys433, Phe434 and a wild-type amino acid residue at position 436. The modified IgG molecules exhibit increased binding affinity for FcRn, as compared with wild-type IgG molecules of the corresponding subclass. The invention also relates to methods involving use of modified IgG molecules and pharmaceutical compositions and chimeric proteins comprising modified IgG molecules. |
